Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer

Journal of International Medical Research

Volumn 41, Issue 1, 2013, Pages 64-71

  Hong, Fanzhen ^a   Li, Yuyang ^a   Xu, Yongping ^a   Zhu, Lin ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Epithelial ovarian cancer; microRNA 221; Prognosis; Real time reverse transcription polymerase chain reaction; Tumour stage

Indexed keywords

MICRORNA 221; TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; NON INVASIVE MEASUREMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84878390980     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513475759     Document Type: Article

References (32)

1. Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(suppl 5): v23-30.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
3. Iwama H, Masaki T and Kuriyama S. Abundance of microRNA target motifs in the 3'-UTRs of 20 527 human genes. FEBS Lett 2007; 581: 1805-1810.
4. Esquela-Kerscher A and Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
5. Kanemaru H, Fukushima S, Yamashita J, et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci 2011; 61: 187-193.
6. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
7. Osaki M, Takeshita F and Ochiya T. MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers 2008; 13: 658-670.
8. Wurz K, Garcia RL, Goff BA, et al. MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer 2010; 49: 577-584.
9. Pineau P, Volinia S, McJunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 2010; 107: 264-269.
10. Liu K, Li G, Fan C, et al. Increased expression of microRNA-221 in gastric cancer and its clinical significance. J Int Med Res 2012; 40: 467-474.
11. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28: 496-504.
12. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33: e179.
13. Tang F, Hajkova P, Barton SC, et al. MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res 2006; 34: e9.
14. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable bloodbased markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105: 10513-10518.
15. Wang JF, Yu ML, Yu G, et al. Serum miR-146a and miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun 2010; 394: 184-188.
16. Li J, Wang Y, Yu W, et al. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun 2011; 406: 70-73.
17. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumourassociated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-675.
18. Friedman RC, Farh KK, Burge CB, et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
19. Kuehbacher A, Urbich C and Dimmeler S. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci 2008; 29: 12-15.
20. Chen Y and Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood 2008; 111: 1217-1226.
21. Davidson-Moncada J, Papavasiliou FN and Tam W. MicroRNAs of the immune system: roles in inflammation and cancer. Ann N Y Acad Sci 2010; 1183: 183-194.
22. Kim YK, Yu J, Han TS, et al. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res 2009; 37: 1672-1681.
23. Gottardo F, Liu CG, Ferracin M, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007; 25: 387-392.
24. Schetter AJ and Harris CC. Plasma microRNAs: a potential biomarker for colorectal cancer? Gut 2009; 58: 1318-1319.
25. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070.
26. Guo HQ, Huang GL, Guo CC, et al. Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/Tcell lymphoma. Dis Markers 2010; 29: 251-258.
27. Galardi S, Mercatelli N, Giorda E, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007; 282: 23716-23724.
28. Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27: 5651-5661.
29. Koelz M, Lense J, Wrba F, et al. Downregulation of miR-221 and miR-222 correlates with pronounced Kit expression in gastrointestinal stromal tumors. Int J Oncol 2011; 38: 503-511.
30. Gramantieri L, Fornari F, Ferracin M, et al. MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res 2009; 15: 5073-5081.
31. Chun-Zhi Z, Lei H, An-Ling Z, et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 2010; 10: 367.
32. Brennecke J, Stark A, Russell RB, et al. Principles of microRNA-target recognition. PLoS Biol 2005; 3: e85.